ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,737.10
-0.31%
S&P ASX All Technology
3,040.10
-0.87%
Brent Oil
77.575
-0.72%
US Dollar vs AUD
1.50388
0.61%
Bitcoin
70,800.00
2.90%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) News

QURE

uniQure NV (QURE)

uniQure NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QURE
DateTimeSourceHeadlineSymbolCompany
03/06/202421:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
03/06/202421:05GlobeNewswire Inc.uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
07/05/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/05/202421:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/05/202421:05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
06/03/202409:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
06/03/202409:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
06/03/202408:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
06/03/202408:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
29/02/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
29/02/202400:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
29/02/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
28/02/202423:05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/02/202408:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
27/02/202408:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
14/02/202408:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202323:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
19/12/202323:05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202311:30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202323:05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202323:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
17/11/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/11/202323:52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/11/202323:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/11/202323:05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
28/10/202301:00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
27/10/202305:38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
27/10/202305:14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202322:05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
06/10/202321:33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Your Recent History

ASX
WPL
Woodside Petroleum
ASX
BHP
BHP
ASX
WES
Wesfarmers
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
ASX
SUN
Suncorp
CCOM
SILVER
SILVER
ASX
ANZ
Australia And New Zealan...
ASX
AMP
AMP
NYSE
MCD
McDonalds
ASX
TLS
Telstra
ASX
MQG
Macquarie
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved